Japanese researchers also reported the beneficial effects of pembrolizumab in a patient with PD-L1+ lung adenocarcinoma, while the CCDC6-RET fusion gene and co-occurring NF1/TP53 mutations were also detected 40. Here, CCDC6 is linked to lung adenocarcinoma.